Even with maximally tolerated statin treatment regimens, atherosclerotic cardiovascular disease (ASCVD) patients with concomitant cardiovascular risk factors may be at risk of major adverse cardiovascular events (MACE).1
Join Prof. Shaun Goodman and leading Australian clinicians Prof. Leon Simons, A/Prof. Karam Kostner and Prof. David Hare in a series of three online presentations and open discussion on the management of high-risk, post-acute coronary syndrome (ACS) patients.
Prof. Goodman’s focus across the sessions will be the ODYSSEY clinical trial program,2,3 along with exploration of trial data of other lipid lowering therapies. Australian experts will use a case based approach to guide discussion around management of primary hypercholesterolaemia and the role of PCSK9 inhibitors, including the monoclonal antibody Praluent® (alirocumab)4, in reducing the risk of recurrent ischaemic events despite maximally tolerated doses of statins with or without ezetimibe.
Each presentation will involve commentary from a leading Australian clinician, who will share their own real-world experiences of using PCSK9 inhibitors in clinical practice before opening up a Q&A session to the audience.
The webinars and Q&A sessions will be held on the 21st July, 27th July and 29th July 2021, at different times to allow as many clinicians as possible to benefit from the discussion.
Register here for the webinar series or register below for individual sessions.
Webinar 2: Why the urgency beyond the ACS emergency?
Tuesday 27th July 2021, 7pm – 8:15pm AEST (evening session)
A/Prof. Karam Kostner, University of Queensland Department of Medicine and Director of Cardiology at Mater Hospital Brisbane, joins Prof. Goodman in a discussion on the importance of early and intensive LDL-C lowering post acute coronary syndrome, supported by the latest real world evidence and guidelines on early intervention.
Webinar 3: How low can we go in our highest risk patients?
Thursday 29th July 2021, 7pm – 8:15pm AEST (evening session)
Prof. David Hare, Senior Cardiologist and Director of Heart Failure Services at Austin Health, joins Prof. Goodman in a discussion that explores efficacy and safety in the reduction of LDL-C for patients at highest ASCVD risk.
These webinars (live or recorded) are intended for healthcare professionals only.
Praluent® is indicated as an adjunct to diet and exercise to reduce LDL-C in adults with primary (heterozygous familial or non-familial) hypercholesterolaemia in patients with moderate to very high cardiovascular risk:
- In combination with a statin, or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with maximum tolerated dose of a statin,
- Alone or in combination with other lipid lowering therapies in patients who are statin intolerant or for whom a statin is contraindicated who are unable to reach LDL-C goals.
Prevention of cardiovascular events
Praluent® is indicated to reduce the risk of cardiovascular events (myocardial infarction, stroke, unstable angina requiring hospitalisation) in adults with established cardiovascular disease, in combination with optimally dosed statins and/or other lipid-lowering therapies.
View the current Australian Product information for Praluent® here.
- Takata K, Nicholls S. Am J Cardiovasc Drugs 2019; 19:113-131.
- Schwartz GG, et al. N Engl J Med 2018; 379:2097–2107.
- Gaudet D, et al. Eur J Prev Cardiol 2020; doi:10.1093/eurjpc/zwaa097.
- PRALUENT® Product Information, 10 January 2020.
®Praluent is a registered trademark of sanofi-aventis australia pty ltd. sanofi-aventis australiapty ltd trading as Sanofi, ABN 31 008 558 807, Talavera Corporate Centre, Building D, 12-24 Talavera Road, Macquarie Park, NSW 2113. Date of Preparation July 2021. MAT-AU-2101421